|Day Low/High||164.67 / 167.99|
|52 Wk Low/High||136.50 / 194.92|
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its business performance, including preliminary financial results for 2016 and a financial outlook for 2017, and an update on its ongoing...
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory...
The most recent short interest data has been released for the 11/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Broadcom released better-than-expected 2016 fourth-quarter results, and its stock on Friday is giving a picture of where the rally could 'broaden to,' says Jim Cramer.
Buy signals have not lasted more than two months, so far.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the results of a Phase 3 study of ORKAMBI ® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) show the potential to...
Vertex Pharma (VRTX) reported lower-than-expected results for the third quarter late yesterday.
More about Vertex's Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2016 and reviewed recent progress with its approved and investigational cystic...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.